Ariad, Execs Beat Fraud Suit Over Failed Leukemia Drug
Ariad Pharmaceuticals Inc. beat a securities fraud action Wednesday after a Boston federal judge said allegations that the company and four officers hid evidence suggesting a promising leukemia drug would fail...To view the full article, register now.
Already a subscriber? Click here to view full article